On February 9, 2020 KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, reported the identification and validation of a novel target, CT-1, for the development of engineered tumor infiltrating lymphocyte (eTIL) therapies for refractory solid tumors. Data from two large-scale CRISPR-Cas9 functional screens using the company’s novel CRISPRomics platform and in vivo validation data will be presented at the Engineering the Genome conference, which takes place in Banff, Alberta, Canada (Press release, KSQ Therapeutics, FEB 9, 2020, View Source [SID1234554056]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Adoptive cell therapies have long been hypothesized to be potentially curative treatments for refractory solid tumors, but their efficacy has been limited by the immunosuppressive tumor microenvironment," said Frank Stegmeier, Chief Scientific Officer of KSQ Therapeutics. "Our CRISPRomics platform enables us to identify gene targets that improve the ability of the T cell to function in this hostile tumor microenvironment. These insights allowed us to develop a pipeline of CRISPR/Cas9 eTIL programs that have the potential to unlock adoptive cell therapy in PD-1 refractory solid tumors."
KSQ’s proprietary CRISPRomics platform was used to identify the top targets across the T- cell genome that increase the efficacy of adoptive T cell transfer therapy (ACT) in PD-1 refractory mouse solid tumor models. CT-1, an undisclosed target identified by KSQ, emerged as a top target from these screens. CT-1-edited T cells produced a 10-fold increase in anti-tumor activity in vivo, and CT-1 edited human TILs exhibit an enhanced cytokine production profile. The data presented support the development of eTIL products with the potential to increase the efficacy of TIL adoptive cell therapy.